Drug
Sitaxsentan clinical trials
Also written Sitaxentan.
- studies test it
- 12
- open now
- 0
- in phase 3
- 6
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sitaxsentan is read from its arms, and is right about nine times in ten.
Testing it · 12
- Sitaxsentan in Proteinuric Chronic Kidney DiseaseCompletedPhase 2University of EdinburghNCT00817037Written as Sitaxsentan
- Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease SubjectsCompletedPhase 2PfizerNCT00810732Written as Open
- Confirming The Sitaxsentan Dose In Patients Undergoing Heart SurgeryCompletedPhase 2PfizerNCT00838383Written as sitaxsentan (Thelin)
- Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term SafetyTerminatedPhase 3PfizerNCT00796510Written as Sitaxsentan
- Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding SildenafilTerminatedPhase 3PfizerNCT00796666Written as Sitaxsentan
- Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)TerminatedPhase 3PfizerNCT00795639Written as Sitaxsentan
- Drug Interaction Between Ritonavir And SitaxsentanWithdrawnPhase 1PfizerNCT01251848Written as Sitaxentan
- Effect Of Rifampin On Pharmacokinetics Of SitaxsentanWithdrawnPhase 1PfizerNCT01251835Written as Sitaxsentan
- A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial HypertensionTerminatedPhase 3PfizerNCT00811018Written as Sitaxsentan
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesTerminatedPhase 1PfizerNCT01244620Written as sitaxentan
- Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsTerminatedPhase 3PfizerNCT01210443Written as Sitaxentan
- A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsTerminatedPhase 3PfizerNCT01204853Written as Sitaxentan
Given in every arm · 1 — sitaxsentan is usual care beside what is tested
Codes
What other systems call sitaxsentan · ClinicalTrials.gg INT003984
- MeSH (NLM) C106276sitaxsentanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) J9QH779MEMSITAXENTANConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C106276 | sitaxsentan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | J9QH779MEM | SITAXENTAN | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.